Latest Articles and Analysis

US monkeypox response: 31% of cases among Black persons, vaccine distribution equity concerns persist.

Innovative HIV medications available but inaccessible: payer barriers block Cabenuva and Apretude access.

Q3 2022 review of HCV drug access across ADAPs, Medicaid, and comprehensive harm reduction programs.

Sustainable advocacy requires long-term investment beyond quarterly financial commitments.

Community-based low-barrier HCV treatment for PWID significantly improves liver health outcomes.

85,000+ fake HIV medication bottles distributed through counterfeiting rings endanger patient safety.

West Virginia's fragmented HIV services across four entities creates barriers; centralization needed.

Federal executive actions protect LGBTQ people as states restrict gender-affirming care and trans rights.

ADAP Advocacy Association Fireside Chats resume with discussions on utilization management and EHE progress.

Conference examines HIV and methamphetamine use intersection among MSM and transgender communities.

2020 CDC HIV surveillance reveals COVID-19's impact on HIV prevention and testing with decreased diagnoses and increased deaths.

Health misinformation undermines vaccine confidence, perpetuates stigma, and drives poor policy decisions.

CANN roundtable examines COVID-19 impacts on public health advocacy, Medicaid expansion, and HIV programs.

Pediatric hepatitis investigations lack typical viruses but show adenovirus and potential COVID-19 involvement.

PrEP access remains limited by payer practices like prior authorizations despite ACA coverage requirements.

Restrictions on abortion and transgender care represent broader attacks on medication access as human right.

Q2 2022 Watch reviewing HCV treatment access across ADAPs, Medicaid, Veterans benefits, and assistance programs.

STI and HCV rates rise despite reduced screening, reflecting chronic public health underfunding.

DOJ clarifies ADA protections for people with opioid use disorder against discrimination.

Pharmaceutical industry changes to 340B implementation impact pricing and accessibility for covered entities.